Document Detail

Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
MedLine Citation:
PMID:  9815565     Owner:  NLM     Status:  MEDLINE    
The human MHC nonrestricted cytotoxic T-cell line TALL-104 exerts potent antitumor effects in animal models with both induced and spontaneous cancers. The present report documents the ability of systemically delivered TALL-104 cells to induce durable clinical remissions in four of four dogs with malignant histiocytosis (MH). The animals received multiple i.v. injections of lethally irradiated (40 Gy) TALL-104 cells at a dose of 10(8) cells/kg, with (two dogs) or without (two dogs) cyclosporin A, followed by monthly boosts. No significant clinical or laboratory toxicities developed during cell therapy; interestingly, a strong correlation was found between the dogs' clinical and immunological responses. One dog with advanced disease (intrathoracic involvement) refractory to chemotherapy achieved a complete remission (CR) within 2 months of the first TALL-104 cell infusion. This dog died 14 months later of unrelated causes: histological analysis of its organs postmortem revealed no evidence of neoplasia, thus confirming the achievement of CR also at the pathological level. The other three dogs with MH that at diagnosis had multiple s.c. and cutaneous lesions and lymphadenopathy, but no visceral involvement, were treated with TALL-104 cells as single agent (no chemotherapy was administered). Two of these dogs achieved a CR soon after cell therapy, and the third dog had two long-lasting partial responses; CR in this dog was later achieved by combined administration of chemotherapy and cell therapy. None of the three dogs that received cell therapy at diagnosis developed visceral disease in the approximately 9-22 months of follow-up. The clinical responses experienced by all four MH cases to TALL-104 cell therapy suggest the high responsiveness of this canine tumor to these xenogeneic effectors and their therapeutic potential even in the most aggressive forms of the disease.
S Visonneau; A Cesano; T Tran; K A Jeglum; D Santoli
Related Documents :
7512085 - A comparative study on tissue processing procedures for the immunohistochemical investi...
10367475 - Pigmented human skin equivalent--as a model of the mechanisms of control of cell-cell a...
2656425 - Immunohistochemical demonstration of histiocytes in normal ectocervical epithelium and ...
17109625 - Neuronal semaphorins regulate a primary immune response.
9693805 - Bulbectomy of neonatal mice induces migration of basal cells from the olfactory epithel...
7083115 - Dark epithelial cells in preneoplastic lesions of the human respiratory tract.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  3     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1999-03-25     Completed Date:  1999-03-25     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1789-97     Citation Subset:  IM    
The Wistar Institute, Philadelphia, Pennsylvania 19104, and Veterinary Oncology Services and Research Center, West Chester, Pennsylvania 19382, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cyclosporine / pharmacology
Cytotoxicity, Immunologic
Dog Diseases / pathology,  therapy*
Histiocytic Sarcoma / pathology,  therapy,  veterinary*
Immunotherapy, Adoptive*
Neoplastic Cells, Circulating
Remission Induction
T-Lymphocytes, Cytotoxic / radiation effects,  transplantation*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myelom...
Next Document:  Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon g...